Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development
Madrigal Pharmaceuticals (Nasdaq: MDGL) has appointed Dr. Michael R. Charlton as Senior Vice President, Clinical Development, effective October 1, 2024. Dr. Charlton brings over 30 years of leadership experience in hepatology, gastroenterology, and liver transplantation, with particular expertise in NASH. He has held academic leadership roles at Mayo Clinic, University of Chicago, and Intermountain Medical Center.
Dr. Charlton's extensive research in NASH has resulted in over 200 publications, including authoring guidelines for the American Association for the Study of Liver Diseases. His appointment reflects Madrigal's commitment to innovation in NASH R&D, following the development of their breakthrough therapy, Rezdiffra (resmetirom).
Madrigal Pharmaceuticals (Nasdaq: MDGL) ha nominato Dr. Michael R. Charlton come Vice Presidente Senior dello Sviluppo Clinico, a partire dal 1 ottobre 2024. Il Dr. Charlton porta con sé oltre 30 anni di esperienza nella leadership nel campo dell'epatologia, gastroenterologia e trapianto di fegato, con particolare expertise in NASH. Ha ricoperto ruoli di leadership accademica alla Mayo Clinic, all'Università di Chicago e all'Intermountain Medical Center.
La vasta ricerca del Dr. Charlton su NASH ha portato a oltre 200 pubblicazioni, inclusa la redazione delle linee guida per l'American Association for the Study of Liver Diseases. La sua nomina riflette l'impegno di Madrigal nell'innovazione nella ricerca e sviluppo di NASH, dopo lo sviluppo della loro terapia rivoluzionaria, Rezdiffra (resmetirom).
Madrigal Pharmaceuticals (Nasdaq: MDGL) ha nombrado al Dr. Michael R. Charlton como Vicepresidente Senior de Desarrollo Clínico, a partir del 1 de octubre de 2024. El Dr. Charlton aporta más de 30 años de experiencia en liderazgo en hepatología, gastroenterología y trasplante de hígado, con especial experiencia en NASH. Ha ocupado roles de liderazgo académico en la Mayo Clinic, la Universidad de Chicago y el Intermountain Medical Center.
La extensa investigación del Dr. Charlton en NASH ha resultado en más de 200 publicaciones, incluyendo la autoría de directrices para la American Association for the Study of Liver Diseases. Su nombramiento refleja el compromiso de Madrigal con la innovación en la I+D de NASH, tras el desarrollo de su terapia innovadora, Rezdiffra (resmetirom).
마드리갈 제약 (Nasdaq: MDGL)는 마이클 R. 찰튼 박사를 2024년 10월 1일부터 임상 개발의 수석 부사장으로 임명했습니다. 찰튼 박사는 간염, 위장병 및 간 이식 분야에서 30년 이상의 경영 경험을 가지고 있으며, NASH에 대한 특별한 전문성을 지니고 있습니다. 그는 메이요 클리닉, 시카고 대학교 및 인터마운틴 메디컬 센터에서 학문적 리더십 역할을 수행했습니다.
찰튼 박사의 NASH에 대한 광범위한 연구는 200편이 넘는 출판물로 이어졌으며, 미국 간 질환 연구 협회의 지침을 저술하는 등을 포함합니다. 그의 임명은 마드리갈이 NASH 연구 및 개발에서 혁신에 대한 의지를 반영하며, 혁신적인 치료제인 Rezdiffra (레즈미티롬)의 개발에 이어 이루어졌습니다.
Madrigal Pharmaceuticals (Nasdaq: MDGL) a nommé Dr. Michael R. Charlton au poste de Vice-Président Senior, Développement Clinique, à compter du 1er octobre 2024. Le Dr Charlton apporte plus de 30 ans d'expérience en matière de leadership en hépato logie, gastroentérologie et transplantation hépatique, avec une expertise particulière en NASH. Il a occupé des postes de direction académique à la Mayo Clinic, à l'Université de Chicago et au Centre Médical Intermountain.
Les recherches approfondies du Dr Charlton sur NASH ont abouti à plus de 200 publications, y compris l'élaboration de directives pour l'American Association for the Study of Liver Diseases. Sa nomination reflète l'engagement de Madrigal envers l'innovation dans R&D NASH, suite au développement de leur thérapie révolutionnaire, Rezdiffra (resmetirom).
Madrigal Pharmaceuticals (Nasdaq: MDGL) hat Dr. Michael R. Charlton zum Senior Vice President für klinische Entwicklung ernannt, mit Wirkung zum 1. Oktober 2024. Dr. Charlton bringt über 30 Jahre Führungserfahrung in der Hepatologie, Gastroenterologie und Lebertransplantation mit, insbesondere im Bereich NASH. Er hat akademische Führungsrollen an der Mayo Clinic, der University of Chicago und dem Intermountain Medical Center innegehabt.
Die umfangreiche Forschung von Dr. Charlton zu NASH hat zu über 200 Veröffentlichungen geführt, einschließlich der Erstellung von Richtlinien für die American Association for the Study of Liver Diseases. Seine Ernennung spiegelt Madrigals Engagement für Innovation in der NASH-F&E wider, nach der Entwicklung ihrer bahnbrechenden Therapie Rezdiffra (resmetirom).
- Appointment of Dr. Michael R. Charlton, a prominent global thought leader in NASH, as Senior Vice President of Clinical Development
- Dr. Charlton brings over 30 years of leadership experience in hepatology and NASH research
- Strengthens Madrigal's position in NASH R&D with expert insights and expanded partnerships in the hepatology community
- Builds upon Madrigal's breakthrough therapy Rezdiffra (resmetirom) in NASH treatment
- None.
CONSHOHOCKEN, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced the appointment of Michael R. Charlton, M.B.B.S., F.R.C.P., as Senior Vice President, Clinical Development, effective October 1, 2024.
Becky Taub, M.D., Chief Medical Officer and President of Research & Development of Madrigal, stated, “I am thrilled to have Dr. Charlton joining the Madrigal team; his deep experience as a researcher and clinician treating patients with NASH will bring powerful new insights and capabilities to Madrigal as we shape the next phase of our R&D strategy.”
Bill Sibold, Chief Executive Officer of Madrigal, added, "Madrigal has established the most advanced and comprehensive clinical development program in NASH, and the appointment of Dr. Charlton reflects our commitment to continue innovating for patients. As a prominent global thought leader in the field, he will provide important strategic perspective to Madrigal and expand our partnerships with the hepatology community.”
Dr. Charlton has more than thirty years of leadership experience in hepatology, gastroenterology, and liver transplantation, with a particular expertise in NASH. He has held academic leadership roles at the Mayo Clinic, where he served as Director of Hepatology, the University of Chicago and Intermountain Medical Center. As Medical Director of the Transplant Institute at the University of Chicago, Dr. Charlton spearheaded innovative clinical programs targeting NASH and other liver disease. His extensive research in the pathophysiology and treatment of NASH has resulted in over 200 publications, including authoring guidelines for the evaluation and management of NASH for the American Association for the Study of Liver Diseases, among many significant contributions to the field, making him a key figure in both clinical and academic hepatology. Dr. Charlton received his M.B.B.S. from the University of London and is a Fellow of the Royal College of Physicians.
“I am excited to begin a new chapter of my career at Madrigal, a company at the forefront of innovation in NASH R&D,” said Dr. Charlton. “After 15 years of research and clinical development, Madrigal has energized the NASH field with a breakthrough therapy in Rezdiffra (resmetirom), and I believe this is just the beginning. I look forward to collaborating with my colleagues at Madrigal and our many partners in the hepatology community to drive new advances in care for patients with this serious disease.”
About NASH
Nonalcoholic steatohepatitis (NASH) is a more advanced form of nonalcoholic fatty liver disease (NAFLD). NASH is a leading cause of liver-related mortality and an increasing burden on healthcare systems globally. Additionally, patients with NASH, especially those with more advanced metabolic risk factors (hypertension, concomitant type 2 diabetes), are at increased risk for adverse cardiovascular events and increased morbidity and mortality.
Once patients progress to NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), the risk of adverse liver outcomes increases dramatically. NASH is rapidly becoming the leading cause of liver transplantation in the U.S. and is already the leading cause in women.
Madrigal estimates that approximately 1.5 million patients have been diagnosed with NASH in the U.S., of which approximately 525,000 have NASH with moderate to advanced liver fibrosis. Madrigal plans to focus on approximately 315,000 diagnosed patients with NASH with moderate to advanced liver fibrosis under the care of the liver specialist physicians during the launch of Rezdiffra.
NASH is also known as metabolic dysfunction associated steatohepatitis (MASH). In 2023, global liver disease medical societies and patient groups came together to rename the disease, with the goal of establishing an affirmative, non-stigmatizing name and diagnosis. Nonalcoholic fatty liver disease (NAFLD) was renamed metabolic dysfunction-associated steatotic liver disease (MASLD); NASH was renamed MASH; and an overarching term, steatotic liver disease (SLD), was established to capture multiple types of liver diseases associated with fat buildup in the liver. In addition to liver disease, patients with MASH have at least one related comorbid condition (e.g., obesity, hypertension, dyslipidemia, or type 2 diabetes).
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH.
For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
Who did Madrigal Pharmaceuticals (MDGL) appoint as Senior Vice President, Clinical Development?
What is Dr. Michael R. Charlton's expertise relevant to Madrigal Pharmaceuticals (MDGL)?
What is the significance of Dr. Charlton's appointment for Madrigal Pharmaceuticals (MDGL)?
What is Madrigal Pharmaceuticals' (MDGL) breakthrough therapy for NASH?
